Deep Genomics Stock

Deep Genomics is using artificial intelligence to build a new universe of life-saving genetic therapies.

Sign up today and learn more about Deep Genomics Stock

Invest in or value your shares in one or many pre-IPO companies through an EquityZen investment vehicle.

About Deep Genomics Stock

The future of medicine will rely on artificial intelligence, because biology is too complex for humans to understand. At Deep Genomics, our geneticists, molecular biologists and chemists develop new ways of detecting and treating disease using our biologically accurate artificial intelligence technology.

Funding History

November 2015	$3.7M
September 2017	$13.0M

Management

Co-Founder

Hannes Bretschneider

Research Scientist & Engineer

Alice Gao

Co-Founder

Hui Yuan Xiong

Co-Founder

Andrew Delong

Co-Founder and CEO

Brendan Frey

Press

patents - Apr, 13 2024

Systems and methods for determining effects of therapies and genetic variation …

patents - Apr, 13 2024

Oligonucleotide therapy for wolman disease and cholesteryl ester storage …

patents - Apr, 13 2024

System and method for training neural networks

patents - Apr, 13 2024

Neural network architectures for linking biological sequence variants based on …

patents - Apr, 13 2024

Oligonucleotide therapy for stargardt disease

Trending Companies

Join 630,000+ Investors and Shareholders

On our trusted digital marketplace for private companies

EquityZen Recognized As:

Why EquityZen?

EquityZen helps investors to access private companies and their employees to sell shares.

Join Now

Investment opportunities posted on this website are "private placements" of securities that are not publicly traded, are subject to holding period requirements, and are intended for investors who do not need a liquid investment. Investing in private companies may be considered highly speculative and involves a high degree of risk, including the risk of substantial loss of investment. Investors must be able to afford the loss of their entire investment. See our Risk Factors for a more detailed explanation of the risks involved by investing through EquityZen’s platform.

EquityZen Securities LLC (“EquityZen Securities”) is a subsidiary of EquityZen Inc. EquityZen Securities is a broker/dealer registered with the Securities Exchange Commission and is a FINRA/SIPC member firm.

Equity securities are offered through EquityZen Securities. Check the background of this firm on FINRA’s BrokerCheck.

EquityZen Inc. was awarded a 2023 Fintech Breakthrough Award by Tech Breakthrough LLC on or about March 23, 2023, based on the prior calendar year and covering calendar year 2023, and has compensated Tech Breakthrough LLC for use of its name and logo in connection with the award. Tech Breakthrough LLC is a third party and has no affiliation with EquityZen.

EquityZen.com is a website operated by EquityZen Inc. ("EquityZen"). By accessing this site and any pages thereof, you agree to be bound by our Terms of Use.
EquityZen and logo are trademarks of EquityZen Inc. Other trademarks are property of their respective owners.
© 2024 EquityZen Inc. All rights reserved.